215 First Street
About Neon Therapeutics
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Founders: James Allison, Ed Fritsch, Nir Hacohen, and Eric Lander
CEO: Hugh O'Dowd
CBO: Robert Ang
CTO: ED Fritsch
CMO: Barbara Weber
CFO: Daniella Beckman
Please click here for Neon job opportunities.
36 articles with Neon Therapeutics
We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2017.
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a ...
Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and Neon Therapeutics, Inc. (NASDAQ: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced a research collaboration using Natera's Signatera™ (RUO) circulating tumor DNA (ctDNA) assay as a biomarker to assess treatment response to NEO-PV-01 in Neon Therapeutics' NT-002 clinical trial.
For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.
Neon Therapeutics to Present Data from Ongoing Phase 1b NT-001 Clinical Trial at the European Society for Medical Oncology 2018 CongressCompany to Host Investor Conference Call and Webcast on October 22, 2018 at 8:00 a.m. ET
Neon Therapeutics, Inc. will be presented in an upcoming oral presentation at the European Society for Medical Oncology (ESMO) 2018 Congress taking place October 19-23, 2018 in Munich, Germany.
Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, taking place November 9-11, 2018 in Washington, D.C.
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
Cambridge, Massachusetts-based Neon Therapeutics is launching an initial public offering (IPO) of 6,250,000 shares of common stock at a price offering of $16 per share.
Eight biotechs launched initial public offerings (IPO) in May, April wasn’t as hot a month, with only two. But June is off to a good start with two.
Neon Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) and hopes to raise $115 million.
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
Neon Therapeutics Expands Board of Directors With Leading Experts in Cancer Drug Discovery and Corporate Finance
Neon Therapeutics announced the expansion of the company’s Board of Directors with the addition of leading experts in translational cancer drug discovery and corporate finance.
12/12/2017A look at what three ex-Genentech employees have accomplished at Denali so far.
Neon Therapeutics and Merck will collaborate on a Phase 1b clinical trial that will examine the safety, tolerability and preliminary efficacy of NEO-PV-01 in combination with KEYTRUDA, pemetrexed and carboplatin in patients with untreated advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
The company announced the successful completion of an additional $36 million extension to its Series B financing.
Vedantra Pharmaceuticals Extends Research Collaboration With Neon Therapeutics to Develop Novel Cancer Immunotherapies
Under the extended agreement, Vedantra and Neon will continue to build on research exploring the potential benefits of combining Vedantra's cutting-edge, lymph node targeting amphiphile technology with Neon's innovative capabilities in neoantigen vaccine research.